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cross-over on progression in approximately 40%. The results 
of this trial are so striking that they almost challenge the 
dogma for a phase 3 study of chemotherapy + PARP inhibi-
tors versus chemotherapy alone to demonstrate efficacy and 
achieve regulatory approval.
Thürlimann: I think they are a promise as of today, but a re-
alistic promise. We urgently need adequate trials to establish 
the clinical position for these drugs which showed encourag-
ing activity. Translational research in association with these 
clinical investigations especially in the adjuvant setting are of 
paramount importance.
Question 2: Do We Have More Insight in the Use of 
 Bevacizumab in Metastatic Breast Cancer? 
Bonnefoi: The results of RIBBON-1 [6] confirm the benefit seen 
in previous trials. A new combination can be added on the list 
in first-line therapy: bevacizumab + capecitabine. However, the 
theme of the ASCO meeting was ‘Personalizing Cancer Care’: 
chemotherapy combined with bevacizumab is one of the options 
for patients with metastatic breast cancer, but not the only one.
Cardoso: The promise of anti-angiogenic therapy has taken 
too long to materialise. Bevacizumab seems to be only mildly 
active in metastatic breast cancer and only when given early 
on, specifically as first-line treatment. It is also associated with 
potentially serious and even fatal side effects, and with too 
high costs. It is therefore indispensible to keep the research 
efforts focused on finding predictive markers of response/re-
sistance that may help us to better select the patients who can 
really benefit from this agent.
Question 1: PARP Inhibitors in Triple Negative Breast 
Cancer. Still a Promise or a Reality? 
Bonnefoi: Definitely PARP (poly(ADR-ribose)polymerase) 
inhibitors are a reality both in combination with chemother-
apy and as a single agent – see the phase 1 trial published in 
the New England Journal of Medicine [1] (we don’t often see 
a phase 1 in the NEJM). In combination with chemotherapy 
in patients with metastatic breast cancer a phase 3 trial is now 
ongoing in the US. Other trials are under development in 
 Europe. Many questions need to be answered: Which is the 
best chemotherapy to combine with a PARP inhibitor? How 
to define BRCAness in clinic? How to go beyond breast and 
ovarian cancer indications?
Cardoso: They are still only a promise but with very high 
hopes regarding their potential to help treat this aggressive 
form of breast cancer. A phase 3 trial should be launched 
without delay to provide the level of evidence needed to have 
this treatment approved and reimbursed, if the very promis-
ing phase 2 data are confirmed.
Coleman: Defective DNA repair has been elegantly demon-
strated to be a major abnormality in hereditary and basal-like 
triple negative tumours [2, 3]. PARP inhibitors exploit this de-
fect and, either alone or in combination with platinum based 
chemotherapy, have been shown in two studies presented at 
ASCO 2009 to have remarkable activity [4, 5]. Indeed in the 
randomised phase 2 study presented by O’Shaughnessy [2], 
significant benefit not only in response rates and PFS were 
seen, but also overall survival was significantly improved with 
BSI-201 in combination with carboplatin and gemcitabine 
compared with the same chemotherapy agents alone, despite 
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Coleman: Presentation of the RIBBON-1 data at ASCO 2009 
demonstrated that bevacizumab clearly augments the efficacy 
of a range of single-agent chemotherapy regimens including 
anthracyclines, paclitaxel and capecitabine. The results add to 
the previously positive E2100 and AVADO trials. However, 
the challenge remains that we still have no validated biomar-
ker to identify patients most likely to benefit, and the ben-
efits are quite modest when compared with other approved 
targeted agents such as trastuzumab. Until bevacizumab be-
comes a truly targeted treatment, rather than an option for 
all, it will remain unaffordable for the majority of health care 
systems and not a cost effective advance in the management 
of advanced malignancy. As a proof of principle and demon-
stration of broad activity with acceptable toxicity, RIBBON-1 
is an important study; we now need to use the biological mate-
rials collected in the trials to define the responsive sub-popu-
lation.
Thürlimann: We have some insight as first-line combination 
therapy but the role of bevacizumab has not sufficiently been 
explored. This is especially the case for the optimal duration 
of the first-line treatment.
Question 3: Bisphosphonates as Anticancer Treatment 
in Early Breast Cancer. Are We Ready for Clinical 
Practice? 
Bonnefoi: See Rob Coleman.
Cardoso: Not yet. A single, relatively small adjuvant trial 
should not lead to a change in clinical practice, except in spe-
cial circumstances, which in my opinion it is not the case. A 
confirmatory study is necessary. However, if confirmed these 
are very exciting data since they represent a paradigm change 
and the ‘discovery’ of a new class of anticancer agents. The 
biological rationale exists and, since these agents will also be 
of great value for bone health, particularly in postmenopausal 
women receiving adjuvant aromatase inhibitors, their place in 
the adjuvant treatment of breast cancer will certainly strongly 
increase. However several important questions remain un-
answered, particularly regarding the frequency of adminis-
tration, dosing and type of bisphosphonate. These questions 
have also important economic implications that should not be 
overlooked.
Coleman: Metastatic bone disease results from the interac-
tions between cancer cells in the bone marrow microenviron-
ment and normal bone cells, thereby providing the rationale 
for bone-targeted therapies. Bisphosphonates interrupt the 
vicious cycle within the marrow microenvironment and may 
also have direct effects on tumour cells, especially when ad-
ministered in combination with chemotherapy [7]. Recent 
data with zoledronic acid, notably from the ABCSG-12 trial 
[8], supported by previous studies with oral clodronate [9, 10] 
suggest that bone targeted treatments may indeed modify the 
course of the disease and reduce recurrence rates. However, 
ABCSG-12 studied a very specific population of oestrogen re-
ceptor positive (ER+) premenopausal women receiving endo-
crine treatment and the results may not apply to the broader 
range of breast cancer patients encountered in clinical prac-
tice. The results of ongoing large metastasis prevention trials 
in breast cancer (NSABP-B34, AZURE) are required before 
routine use of adjuvant bisphosphonates, outside the context 
of clinically relevant treatment induced bone loss, can be rec-
ommended.
Thürlimann: We are not yet completely ready for clinical 
practice. We need convincing and unequivocal evidence for 
their use in different patient and treatment settings. ABCSG-
12 is a paradigmatic trial in a small, well selected population 
with specific and partially experimental treatments. It is a pos-
itive ‘proof of principle’. The following larger trials will soon 
give more information in broader populations with ‘standard’ 
treatments and with a higher event rate.
Question 4: Gennomic Signature and Early Breast  
Cancer. When and Why? 
Bonnefoi: See Fatima Cardoso.
Cardoso: The accurate identification of the patients that need 
adjuvant chemotherapy is one of the most important dilem-
mas in clinical practice. The commonly used clinico-pathologi-
cal factors are important but not sufficient to help us in this 
selection. New tools are therefore of crucial importance. Two 
tests are in the most advanced phase of development: Mam-
maPrint and Oncotype DX. Both are undergoing prospective 
validation in large adjuvant trials: MINDACT and TAILORx. 
Until these tools have achieved level 1 evidence from prospec-
tive validation, they should not be widely used in clinical prac-
tice, in the same way as a new drug is very rarely approved on 
the basis of phase 2 data only. I therefore disagree with the 
recent endorsement of these tests by the St. Gallen consensus, 
even if it was done only for cases where doubt persists. This 
endorsement should have waited for the end of recruitment 
of the important prospective trials. All these new prognostic 
genomic tools seem to reflect the same biological phenom-
enon, which is proliferation. This is probably also the reason 
why they are also associated with a better response to chemo-
therapy. New signatures reflecting other important pathways 
need to be developed and combined with the existing ones to 
increase their prognostic potential.
Coleman: We are witnessing an explosion of information on 
molecular phenotyping and generation of genetic signatures 
in breast cancer aimed at either accurately defining prognosis 
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or predicting response to treatment. Clearly there is a great 
need to characterise individual tumours accurately to enable 
treatment to be personalised, thereby minimising the risk of 
overtreatment and utilising the best combination of agents in 
an individual patient. Currently available tools (Oncotype DX 
and MammaPrint) appear to accurately define a low-risk pop-
ulation who do not require chemotherapy. However, further 
prospective validation of both techniques is needed and in 
progress (TAILORx and MINDACT), while at present, pre-
dictive signatures remain a research tool and are hypothesis 
generating only. It will also be important to show that these 
complex and expensive profiling methods truly do out-per-
form routine pathological assessment of tumour grade with 
high-quality immunohistochemistry for ER, PgR, HER2 and 
proliferation (Ki-67 or similar).
Thürlimann: We do not routinely use genomic signatures. We 
are in the lucky position to have access to high-quality pathol-
ogy including continuous external quality assurance. We ac-
knowledge that in other environments they may play a more 
important role for the daily routine. We should await the re-
sults of ongoing prospective randomised trials before we draw 
new conclusions. 
Question 5: Aromatase Inhibitors in the Adjuvant  
Setting. Upfront or Not Upfront? 
Bonnefoi: See Beat Thürlimann.
Cardoso: The recent results of the BIG 1-98 trial provide the 
rationale for starting more often with an aromatase inhibitor 
(AI) upfront since they have shown that one can safely switch 
to tamoxifen after two years of an AI, in case tolerance is not 
optimal. Tolerability of AIs is a huge problem in clinical prac-
tice, particularly due to arthralgia and myalgia. The possibil-
ity of prescribing the ‘reverse’ sequence allows women who 
do not optimally tolerate the AI to safely shift to tamoxifen, 
while at the same time receiving the AI during the first two 
years when the rate of relapse is higher.
Coleman: Trials of the aromatase inhibitors in postmenopau-
sal ER+ breast cancer have consistently shown improved ef-
ficacy over tamoxifen and a favourable toxicity profile with 
the exception of more frequent musculoskeletal side effects 
and accelerated bone loss. However, debate continues about 
whether an AI should replace or be added in sequence to 
treatment with tamoxifen. This is based on both the biologi-
cal question as to whether two endocrine approaches are bet-
ter than one as well as health economics. Both up-front and 
sequence/switching strategies have been shown to clearly im-
prove disease-free survival (DFS) and also produce small sur-
vival gains that are of borderline statistical significance. The 
BIG1-98 trial confirms that an AI should be part of routine 
treatment for the vast majority of women with postmenopau-
sal ER+ breast cancer. However, this trial has failed to show 
any significant difference in outcome between the immediate 
or sequencing strategies. Only the TEAM trial comparing 5 
years exemestane to a tamoxifen-exemestane sequence in 
>9000 women is powered to definitively address this question. 
It is anticipated that the 5 year results from TEAM will be 
available in 2010. Until then a strategy of immediate AI for in-
termediate- to high-risk patients and a sequence of tamoxifen 
- AI or AI - tamoxifen for low- to intermediate-risk patients 
remains a reasonable approach.
Thürlimann: After the recent presentations in San Antonio 
and St. Gallen we clearly prefer the upfront use of AI if they 
are prescribed.
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